Skip to main content
SpringerLink
Log in

Metal binding by pharmaceuticals. part 2. interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192

  • Platelets and Thrombosis Bioinorganic Interactions
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Formation constants for the calcium(II), copper(II), iron(II), magnesium(II), manganese(II) and zinc(II) complexes ofdl-NN'-dicarboxamidomethyl-NN'-dicarboxymethyl-1,2-diaminopropane (ICRF 198) and the 1,2-diamino-butane homologue (ICRF 226) have been measured potentiometrically at 37°C andI=150 mmol dm−3 [NaCl]. The constants are used in computer simulation models to assess the relative avidity of these compounds for biologically essential metal ionsin vivo. It is shown that the agents interact similarly with all of the ions studied except those of zinc(II), which are particularly strongly chelated by the hydrolysis product of ICRF 192.

This effect could be responsible for the difference in cytotoxicity exhibited by the antitumour agent ICRF 159 (Razoxane) and its inactive homologue ICRF 192. However, the mechanism through which this might occur remains unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A. Cole, P.M. May andD.R. Williams,Metal binding by pharmaceuticals, Part 1. Copper(II) and zinc(II) interactions following ethambutol administration, Agents and Actions11, 296–305 (1981).

    Google Scholar 

  2. A.M. Creighton, K. Hellmann andS. Whitecross,Antitumour activity in a series of bisdiketopiperazines, Nature222, 384–385 (1969).

    PubMed  Google Scholar 

  3. K. Hellmann andK. Burrage,Control of metastases by ICRF 159, Nature224, 273–275 (1969).

    PubMed  Google Scholar 

  4. A.J. Salsbury, K. Burrage andK. Hellmann,Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic, Br. Med. J.4, 344–346 (1970).

    PubMed  Google Scholar 

  5. A.J. Salsbury, K. Burrage andK. Hellman,Histological analysis of the antimetastatic effect of (±)-1,2-bis(3,5-dioxopiperazin-1-yl) propane, Cancer Res.34, 843–849 (1974).

    PubMed  Google Scholar 

  6. A.M. Creighton,3,5-Dioxopiperazine derivatives, U.K. Pat. No. 1234935 (1972).

  7. M.T. Bakowski,ICRF 159, (±)1,2-di(3,5-Dioxopiperazin-1-yl) propane NSC-129 943, Razoxane, Cancer Treat. Rep.3, 95–107 (1976).

    Google Scholar 

  8. H.B.A. Sharpe, E.O. Field andK. Hellmann,Mode of action of the cytostatic agent ICRF 159, Nature226, 524–526 (1970).

    PubMed  Google Scholar 

  9. A.M. Creighton andG.D. Birnie,Biochemical studies on growth inhibitory bisdioxopiperazines 1. Effect on DNA, RNA and protein synthesis in mouse-embryo fibroblasts, Int. J. Cancer.5, 47–54 (1970).

    PubMed  Google Scholar 

  10. T.C. Stephens,An Investigation of the Effects of the Antitumour Agent ICRF 159 on the Growth of BHK-21 S Cells in Culture, PhD thesis, University of London 1974.

  11. U. Witting, H.P. Bertram, E. Schumacher andG. Ritter,Der Einfluss der Bis-dioxopiperazine ICRF 159 und ICRF 154 auf die Cadmium-Ausscheidung im Urin bei Cadmium-Vergifteten Ratten, Int. Arch. Occup. Environ. Health42, 365–373 (1979).

    Article  PubMed  Google Scholar 

  12. U. Witting andE. Hultsch,Lead elimination by ICRF 158 in rats after chronic lead exposure, Int. Arch. Occup. Environ. Health48, 89–98 (1981).

    Article  PubMed  Google Scholar 

  13. D.D. Von Hoff, D. Howser, B.J. Lewis, J. Holcenberg, R.B. Weiss andR.C. Young,Phase I study of ICRF 187 using a daily for 3 days schedule, Cancer Treat. Rep.65, 249–252 (1981).

    PubMed  Google Scholar 

  14. K.M. Dawson,Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells, Biochem. Pharmacol.24, 2249–2253 (1975).

    Article  PubMed  Google Scholar 

  15. A.I. Vogel,A Textbook of Quantitative Inorganic Analysis. Longman, London 1961.

    Google Scholar 

  16. D. Dyrssen, D. Jagner andF. Wengelin. InComputer Calculations of Ionic Equilibria and Titration Procedures, p. 204. Wiley, London 1968.

    Google Scholar 

  17. C.K. Prout, D.S. Sanderson andM.C. Couldwell,N,N-Methylethylene-bis(N-methylcarbamyl-glycinato) copper(II) dihydrate, Cryst. Struct. Commun.8, 181–188 (1979).

    Google Scholar 

  18. G. Berthon, P.M. May andD.R. Williams,Computer simulation of metal ion equilibria in biofluids. Part 2. Formation constants for zinc(II) citrate-cystinate binary and ternary complexes and improved models of low-molecular-weight zinc species in blood plasma, J. Chem. Soc. Dalton 1433–1438 (1978).

  19. P.M. May, D.R. Williams, P.W. Linder andR.G. Torrington,The use of glass electrodes for the determination of formation constants. Part 1. A definitive method for calibration, Talanta,29, 249–256 (1982).

    Article  Google Scholar 

  20. P.M. May, P.W. Linder andD.R. Williams,Computer simulation of metal-ion equilibria in biofluids: Models for the low-molecular-weight complex distribution of calcium(II), magnesium(II), manganese(II), iron(III), copper(II), zinc(II), and lead(II) ions in human blood plasma, J. Chem. Soc. Dalton 588–595 (1977).

  21. P.M. May andD.R. Williams,Computer simulation of chelation therapy. Plasma mobilizing index as a replacement for effective stability constant, FEBS Lett.78, 134–138 (1977).

    Article  PubMed  Google Scholar 

  22. A.M. Creighton,Mechanism of action of ICRF 159, Proc. 12th Int. Cancer Congress, p. 83. Pergamon Press, Oxford 1978.

    Google Scholar 

  23. L.W. Oberley andG.R. Buettner,Role of superoxide dismutases in cancer, Cancer Res.39, 1141–1149 (1979).

    PubMed  Google Scholar 

  24. N.G. Westman andS.L. Marklund,Copper-and zinc-containing superoxide dismutase and manganesecontaining superoxide dismutase in human tissues and human malignant tumours, Cancer Res.41, 2962–2966 (1981).

    PubMed  Google Scholar 

  25. R.S. Kass andR.W. Tsien,Multiple effects of calcium antagonists on plateau currents in cardiac Purkinje fibers, J. Gen. Physiol.66, 169–192 (1975).

    PubMed  Google Scholar 

  26. I.W. Taylor andN.M. Bleehen,Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro, Br. J. Cancer36, 493–500 (1977).

    PubMed  Google Scholar 

  27. R.J. Woodman, R.L. Cysyk, I. Kline, M. Gang andJ.M. Venditti,Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-13127) against early mouse L1210 leukemia with ICRF 159 (NSC-129943), Cancer Chemother. Rep.59, 689–695 (1975).

    PubMed  Google Scholar 

  28. N.R. Bachur, S.L. Gordon andM.V. Gee,The general mechanism of microsomal activation of quinone anticancer agents to free radicals, Cancer Res.38, 1745–1750 (1978).

    PubMed  Google Scholar 

  29. E.H. Herman, R. Mhatre andD. Chadwick,Modification of some of the toxic effects of daunomycin (NSC-82151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129943), Toxicol. Appl. Pharmacol.27, 517–526 (1974).

    Article  PubMed  Google Scholar 

  30. E.H. Herman, V.J. Ferrans, W. Jordan andB. Ardalan,Reduction of chronic daunorubicin cardiotoxicity by ICRF 187 in rabbits, Res. Comm. Chem. Path. Pharmacol.31, 85–87 (1981).

    Google Scholar 

  31. C.E. Meyers, C.B. Simone, L. Gianni, R. Green, R.W. Klecker andM.F. Hendrickson,The role of doxorubicin-iron complex in superoxide production and membrane damage, Proc. Am. Assoc. Cancer Res.22, 28 (1981).

    Google Scholar 

  32. M. Gosálvez, M.F. Blanco, C. Vivero andF. Valles,Quelamycin, a new derivative of adriamycin with several possible therapeutic advantages, Eur. J. Cancer14, 1185–1190 (1978).

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Zhong-Xian Huang & Peter M. May

    Present address: Department of Chemistry, Fudan University, Shanghai, The People's Republic of China

Authors and Affiliations

  1. Department of Applied Chemistry, University of Wales Institute of Science and Technology, CF1 3NU, Cardiff

    Zhong-Xian Huang, Peter M. May, Kevin M. Quinlan, David R. Williams & Andrew M. Creighton

  2. Cellular Pharmacology and Antitumour Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, WC2A 3PX, London, UK

    Zhong-Xian Huang, Peter M. May, Kevin M. Quinlan, David R. Williams & Andrew M. Creighton

Authors
  1. Zhong-Xian Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter M. May
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin M. Quinlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David R. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew M. Creighton
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Part 1 is Ref. [1].

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, ZX., May, P.M., Quinlan, K.M. et al. Metal binding by pharmaceuticals. part 2. interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192. Agents and Actions 12, 536–542 (1982). https://doi.org/10.1007/BF01965940

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01965940

Keywords

Search

Navigation